ABCC2 and Dubin-Johnson syndrome: This case provided a rare opportunity to assess the impact of MRP2 mutations associated with Dubin–Johnson syndrome on the pharmacokinetics of vincristine and strongly indicates that a marked dose reduction should be recommended.